Cancer

The Readout Meghana Keshavan

STAT Plus: Can JAK inhibitors bolster checkpoint inhibitors? 

In the Lab Angus Chen

STAT Plus: New immunotherapy combination could ‘change the landscape’ of cancer treatment

Health Angus Chen

STAT Plus: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Will Geron be acquired? The long-short view

Exclusive John Wilkerson

NIH wanted to make cancer research more diverse. The effort turned out to be a costly failure

The Readout Elaine Chen

Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know

First Opinion Sanket S. Dhruva and Rita F. Redberg

Blood tests for cancer detection aren’t yet ready for prime time

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Listen: Psychedelics at the FDA, ASCO recap, & MorphoSys update

Biotech Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care

The Readout Elaine Chen

STAT Plus: Operation Warp Speed but for rare disease

Adam's Take Adam Feuerstein

STAT Plus: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug

Biotech Matthew Herper, Adam Feuerstein, and Angus Chen

STAT Plus: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’

Biotech Angus Chen

STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

Biotech Matthew Herper

STAT Plus: Delfi Diagnostics announces key data, study design for its liquid biopsy test

Biotech Matthew Herper

STAT Plus: ASCO24: AstraZeneca won cancer’s big meeting — again. Will that help it fulfill its $80 billion ambition?

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth

Health Angus Chen

Palliative care for cancer patients is found to be as effective given virtually as in person

Pharma Matthew Herper

STAT Plus: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer

Biotech Adam Feuerstein

STAT Plus: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment

Pharma Andrew Joseph

STAT Plus: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug

Pharma Angus Chen

STAT Plus: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers

Biotech Elaine Chen

STAT Plus: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone

Biotech Adam Feuerstein

STAT Plus: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment

Health Angus Chen

How can hospitals boost cancer screening rates? Researchers report that an AI helped

The Readout Meghana Keshavan

STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates

Biotech Matthew Herper

STAT Plus: For one rare type of lung cancer, Pfizer pill reduces progression by 81%

The Readout Meghana Keshavan

STAT Plus: Biotech’s most interesting fundraisings from the last week